SUNPHARMA · Sun Pharmaceutical Industries Limited · BSE · Filed 10 Jul · 1 min read

Sun Pharma to Report Q1 FY2027 Results on 31 July

The board meets that day to approve unaudited standalone and consolidated results for the quarter ended 30 June 2026.

What was filed

Sun Pharmaceutical Industries has given advance notice, under Regulation 29 of SEBI's listing rules, that its Board of Directors will meet on Friday, 31 July 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, along with connected matters. This is a scheduling intimation only — the filing carries no financial figures.

Trading window

The company confirmed its trading window has been closed since Wednesday, 1 July 2026 and will remain shut until Sunday, 2 August 2026. Such closures are routine ahead of results and restrict trading in the company's securities by designated persons around unpublished price-sensitive information.

The notice fixes the date on which Sun Pharma's first-quarter FY2027 numbers become public; the results themselves, not this intimation, will carry the substance for holders.